Merck MRK announced data from the phase III KEYFORM-007 study, which evaluated a fixed-dose combination of its anti-LAG-3 ...

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial ...

Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Merck (MRK) stock is in focus as a Phase 3 trial for its cancer drug Keytruda in colorectal cancer patients did not meet ...

A phase III trial of the fixed-dose combination of the LAG-3 inhibitor favezelimab and pembrolizumab (Keytruda) failed to ...

Merck's Phase III KEYFORM-007 trial, testing a combination of favezelimab and Keytruda, failed to meet its primary endpoint ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Merck is studying Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, in a raft of trials across a wide variety of cancers and treatment settings. The company is ...

Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...

Merck & Co.’s stock fell 0.5% premarket Wednesday, after the drug company said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal ...

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...